Feiyu Liu

Feiyu Liu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LWLuqiong Wang
Luqiong Wang
JCJiaojiao Chen
Jiaojiao Chen
HLHuixiang Li
Huixiang Li
LWLin Wang
Lin Wang
FLFeiyu Liu
Feiyu Liu
XJXiaoli Jiang Jiang
Xiaoli Jiang Jiang
Objective: To integrate pharmacovigilance and network pharmacology methods for a comprehensive analysis of the potential adverse reactions of complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor (FcRn) inhibitors (efgartigimod, rozanolixizumab), and to explore their toxicity mechanisms, thereby providing a reference for rapidly understanding the safety of these two novel classes of biologics in the treatment of myasthenia gravis (MG).Methods: We extracted adverse event (AE) reports for these five drugs from the FDA Adverse Event Reporting System (FAERS) database, limited to the period since their FDA approval for the treatment of MG. Reports were further restricted to those where the drug was listed as the primary suspect (PS) and the indication (INDI) was “MG”. Signal detection was performed using the Reporting Odds Ratio (ROR) method, the UK Medicines and Healthcare products Regulatory Agency (MHRA) method, and the Bayesian Confidence Propagation Neural Network (BCPNN) method. Additionally, network pharmacology was employed to analyze the toxicity mechanisms of the system organ categories (SOCs) specifically associated with complement C5 inhibitors and FcRn inhibitors.Results: Signal detection of AE reports associated with these five drugs revealed previously unlabeled positive signals, including: eculizumab (gastric cancer, embolic stroke), ravulizumab (psoriatic arthropathy, hypoacusis, peripheral vascular disorders), zilucoplan (weight increased, weight decreased), efgartigimod (metastases to liver, hepatic failure, nephrolithiasis, dysuria, Prostatitis, prostate cancer, Angina pectoris, congestive cardiac failure) and rozanolixizumab (vomiting, dyspepsia). However, the gastric cancer, liver metastasis and prostate cancer were reported within the first 30 days, causal associations cannot be established based on the data presented. Potential toxicity analysis was conducted on noteworthy SOCs for complement C5 inhibitors and FcRn inhibitors, revealing key targets and pathways.Conclusion: This study elucidated the safety profiles of complement C5 inhibitors and FcRn inhibitors in clinical practice through pharmacovigilance analysis, confirming known adverse reactions and identifying several previously unreported ones. Furthermore, network pharmacology analysis revealed potential mechanisms underlying these adverse reactions. These findings provide valuable insights for monitoring and managing risks during treatment with two novel classes of biologics.

7 October 2022 in Medicine
Verified
Journal Article
Open access
CWCheng-Qian Mm Wang
Cheng-Qian Mm Wang
FLFeiyu Liu
Feiyu Liu
WWWei Wang
Wei Wang
Introduction: Lobaplatin is a new platinum-based cytotoxic chemotherapeutic agent. Endostar is an endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate the efficacy and safety of thoracic perfusion of lobaplatin combined with endostar in the treatment of malignant pleural effusions (MPE). Methods: We searched the databases of Pubmed, the Cochrane Library, Embase, WanFang Data, and CNKI to select the studies regarding the efficacy and safety of lobaplatin combined with endostar to treat MPE. A total of 10[3–12] randomized controlled trials with 651 patients were included. Results: The objective response rate (P < .001, odds ratio = 4.08) and disease control rate (P < .001, odds ratio = 3.69) of lobaplatin combined with endostar were significantly higher than lobaplatin alone. In addition, lobaplatin combined with endostar remarkably promoted the quality of life of patients (P < .001, odds ratio = 3.93) compared with lobaplatin alone. Lobaplatin combined with endostar also promoted the quality of life of patients (P < .05, odds ratio = 2.56) compared with cisplatin combined with endostar. At the same time, the leukopenia rate (P < .05, odds ratio = .40) and the incidence of nausea and vomiting (P < .05, odds ratio = .38) of lobaplatin combined with endostar were significantly lower than that of cisplatin combined with endostar. Conclusions: The efficacy of lobaplatin combined with endostar was superior to lobaplatin alone. The safety was higher than cisplatin combined with endostar through thoracic perfusion in treating MPE, which indicated that lobaplatin combined with endostar could be the effective agent for controlling MPE.

1 March 2018 in Medicine
Verified
Journal Article
Open access
PDF file
WWWei Wang
Wei Wang
DXDong Xing
Dong Xing
YSYingjian Song
Yingjian Song
FLFeiyu Liu
Feiyu Liu
Esophageal cancer is one of the worst malignant digestive neoplasms with poor treatment outcomes. Definitive concurrent chemoradiotherapy (CRT) has become the standard nonsurgical treatment option for locally advanced esophageal cancer. The chemotherapeutic drugs 5-fluorouracil and cisplatin have been most commonly used in CRT of esophageal cancer. However, radiotherapy combined with 5-FU/cisplatin often delivers severe toxicity to patients. S-1 as an oral chemotherapeutic drug exhibits higher anti-tumor activity, less adverse effects, and better biological availability. S-1 also has excellent effects as a CRT regimen for esophageal cancer. A systematic literature search will be performed through January 2018 using MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and Google Scholar for relevant articles published in any language. Randomized controlled trials, prospective comparative studies will be included. All meta-analyses will be performed using Review Manager software. The quality of the studies will be evaluated using the guidelines listed in the Cochrane Handbook. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements will be followed until the findings of the systematic review and meta-analysis are reported. The results of this systematic review and meta-analysis will be published in a peer-reviewed journal. Our study will draw an objective conclusion of the effects of S-1 combined with radiotherapy in the treatment of unresectable esophageal cancer and provide level I evidence for clinical decision makings.

1 May 2026 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
YLYiming Lei
Yiming Lei
XZXingbo Zhang
Xingbo Zhang
WHWeiran Hou
Weiran Hou
XZXiumin Zhang
Xiumin Zhang
ZZZirui Zhou
Zirui Zhou
ZWZhen Wang
Zhen Wang
Background: Esophageal squamous cell carcinoma (ESCC) is a major malignancy of the upper gastrointestinal tract. Owing to limited actionable therapeutic targets, long-term outcomes remain unsatisfactory. This study aimed to investigate the prognostic value of non-myelinating Schwann cells (nmSCs) infiltration in ESCC and to identify potential upstream regulators and underlying mechanisms. Methods: nmSCs infiltration was quantified in ESCC transcriptomic datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) using single-sample gene set enrichment analysis (ssGSEA). Genes associated with nmSC infiltration were identified by weighted gene co-expression network analysis (WGCNA) and correlation analyses. Potential upstream regulators and signaling pathways were explored by pan-cancer analyses in the Tumor Immune Estimation Resource (TIMER) database. nmSCs infiltration and candidate regulator expression were validated in an independent surgical cohort by immunohistochemistry (IHC). In addition, to investigate the regulatory relationship between teashirt zinc finger homeobox 3 (TSHZ3) and neuregulin 1 (NRG1) and their effects on Schwann cells (SCs) function, a co-culture system of ESCC cells and SCs was established. Functional validation was performed by knocking down TSHZ3 in ESCC cells, followed by quantitative real-time polymerase chain reaction (qRT-PCR), Western blot, and Cell Counting Kit-8 (CCK-8) assays. A postoperative prognostic model incorporating nmSC infiltration was subsequently developed. Results: Elevated nmSCs infiltration was significantly associated with poor survival in ESCC. IHC validation further confirmed nmSCs infiltration as an independent prognostic risk factor in patients undergoing surgical resection. Integrated analyses identified TSHZ3 as a potential upstream regulator of SCs infiltration, potentially acting through the NRG1 pathway in ESCC and multiple other tumor types. IHC demonstrated a significant positive correlation between TSHZ3 expression and nmSCs infiltration. Further in vitro functional experiments confirmed that knockdown of TSHZ3 in ESCC cells significantly reduced NRG1 expression levels and inhibited the proliferative capacity of SCs in the co-culture system, providing more direct evidence for the TSHZ3-NRG1 regulatory axis. Conclusions: nmSCs infiltration predicts adverse prognosis in ESCC, and TSHZ3 may promote nmSCs infiltration via the NRG1 signaling axis.